Cannabis - Aspectos regulatorios: posibles usos terapéuticos

Aspectos sobre el uso terapéutico del cannabis

Fuente: PubMed [Internet]. Bethesda (MD): US National Library of Medicine National Institutes of Health; [consulta 25 mayo 2022]. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/

Detalles de búsqueda: (("cannabis"[MeSH Terms] OR "cannabis"[All Fields]) AND ("drug interactions"[MeSH Terms] OR ("drug"[All Fields] AND "interactions"[All Fields]) OR "drug interactions"[All Fields]) AND "humans"[MeSH Terms]) AND ((y_5[Filter]) AND (meta-analysis[Filter] OR review[Filter] OR systematicreview[Filter]))

NOTA - Debido al altísimo nº de los resultados obtenido, las Novedades los años 2019-2022 son entradas formadas por revisiones, revisiones sistemáticas y metaánalisis.

 

2022

• Janecki M, Graczyk M, Lewandowska AA, Pawlak Ł. Anti-Inflammatory and Antiviral Effects of Cannabinoids in Inhibiting and Preventing SARS-CoV-2 Infection. Int J Mol Sci. 10 de abril de 2022;23(8):4170.
• Lord S, Hardy J, Good P. Does Cannabidiol Have a Benefit as a Supportive Care Drug in Cancer? Curr Treat Options Oncol. abril de 2022;23(4):514-25.
• Samanta D. A scoping review on cannabidiol therapy in tuberous sclerosis: Current evidence and perspectives for future development. Epilepsy Behav. marzo de 2022;128:108577 .
• Kolla BP, Hayes L, Cox C, Eatwell L, Deyo-Svendsen M, Mansukhani MP. The Effects of Cannabinoids on Sleep. J Prim Care Community Health. diciembre de 2022;13:21501319221081276.
• Traccis F, Presciuttini R, Pani PP, Sinclair JMA, Leggio L, Agabio R. Alcohol-medication interactions: A systematic review and meta-analysis of placebo-controlled trials. Neurosci Biobehav Rev. enero de 2022;132:519-41.

2021

• Murkar A, De Koninck J, Merali Z. Cannabinoids: Revealing their complexity and role in central networks of fear and anxiety. Neurosci Biobehav Rev. diciembre de 2021;131:30-46.
• Duarte RA, Dahmer S, Sanguinetti SY, Forde G, Duarte DP, Kobak LF. Medical Cannabis for Headache Pain: a Primer for Clinicians. Curr Pain Headache Rep. 9 de octubre de 2021;25(10):64.
• García-Peñas JJ, Gil Nagel-Rein A, Sánchez-Carpintero R, Villanueva-Haba V. Cannabidiol para el tratamiento del síndrome de Lennox-Gastaut y del síndrome de Dravet: recomendaciones de expertos sobre su uso en la práctica clínica en España. Rev Neurol. 10 de septiembre de 2021;73(S01):S1-8.
• Brown JD, Rivera Rivera KJ, Hernandez LYC, Doenges MR, Auchey I, Pham T, et al. Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions. J Clin Pharmacol. agosto de 2021;61 Suppl 2:S37-52.
• Petersen MJ, Bergien SO, Staerk D. A systematic review of possible interactions for herbal medicines and dietary supplements used concomitantly with disease-modifying or symptom-alleviating multiple sclerosis drugs. Phytother Res. julio de 2021;35(7):3610-31.
• MacCallum CA, Lo LA, Boivin M. «Is medical cannabis safe for my patients?» A practical review of cannabis safety considerations. Eur J Intern Med. julio de 2021;89:10-8.
• Solomon HV, Greenstein AP, DeLisi LE. Cannabis Use in Older Adults: A Perspective. Harv Rev Psychiatry. 1 de junio de 2021;29(3):225-33.
• Arnold JC. A primer on medicinal cannabis safety and potential adverse effects. Aust J Gen Pract. junio de 2021;50(6):345-50.
• Franco V, Bialer M, Perucca E. Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research. Neuropharmacology. 1 de marzo de 2021;185:108442.
• Gilmartin CGS, Dowd Z, Parker APJ, Harijan P. Interaction of cannabidiol with other antiseizure medications: A narrative review. Seizure. marzo de 2021;86:189-96.
• Melaragno JI, Bowman LJ, Park JM, Lourenco LM, Doligalski CT, Brady BL, et al. The Clinical Conundrum of Cannabis: Current Practices and Recommendations for Transplant Clinicians: An Opinion of the Immunology/Transplantation PRN of the American College of Clinical Pharmacy. Transplantation. 1 de febrero de 2021;105(2):291-9.
• Wilson M, Klein T, Bindler RJ, Kaplan L. Shared Decision-Making for Patients Using Cannabis for Pain Symptom Management in the United States. Pain Manag Nurs. febrero de 2021;22(1):15-20.

2020

• Narouze S, Strand N, Roychoudhury P. Cannabinoids-based Medicine Pharmacology, Drug Interactions, and Perioperative Management of Surgical Patients. Adv Anesth. diciembre de 2020;38:167-88.
• Amaral Silva D, Pate DW, Clark RD, Davies NM, El-Kadi AOS, Löbenberg R. Phytocannabinoid drug-drug interactions and their clinical implications. Pharmacol Ther. noviembre de 2020;215:107621.
• Namdar D, Anis O, Poulin P, Koltai H. Chronological Review and Rational and Future Prospects of Cannabis-Based Drug Development. Molecules. 20 de octubre de 2020;25(20):E4821.
• Brunetti P, Lo Faro AF, Pirani F, Berretta P, Pacifici R, Pichini S, et al. Pharmacology and legal status of cannabidiol. Ann Ist Super Sanita. septiembre de 2020;56(3):285-91.
• Opitz BJ, Ostroff ML, Whitman AC. The Potential Clinical Implications and Importance of Drug Interactions Between Anticancer Agents and Cannabidiol in Patients With Cancer. J Pharm Pract. agosto de 2020;33(4):506-12.
• Kraft B, Stromer W. [The effects of cannabis and cannabinoids on anesthesia and analgesia during the perioperative period]. Schmerz. agosto de 2020;34(4):314-8.
• Dharmapuri S, Miller K, Klein JD. Marijuana and the Pediatric Population. Pediatrics. agosto de 2020;146(2):e20192629.
• Babalonis S, Walsh SL. Therapeutic potential of opioid/cannabinoid combinations in humans: Review of the evidence. Eur Neuropsychopharmacol. julio de 2020;36:206-16.
• Alves P, Amaral C, Teixeira N, Correia-da-Silva G. Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol. Pharmacol Res. julio de 2020;157:104822.
• Teitel A, Bozimowski G. A Review of the Pharmacology and Anesthetic Implications of Cannabis. AANA J. junio de 2020;88(3):237-44.
• Kovalchuk O, Kovalchuk I. Cannabinoids as anticancer therapeutic agents. Cell Cycle. mayo de 2020;19(9):961-89.
• Carvalho ACA de, Souza GA de, Marqui SV de, Guiguer ÉL, Araújo AC, Rubira CJ, et al. Cannabis and Canabidinoids on the Inflammatory Bowel Diseases: Going Beyond Misuse. Int J Mol Sci. 22 de abril de 2020;21(8):E2940.
• Greger J, Bates V, Mechtler L, Gengo F. A Review of Cannabis and Interactions With Anticoagulant and Antiplatelet Agents. J Clin Pharmacol. abril de 2020;60(4):432-8.
• Yoo HB, DiMuzio J, Filbey FM. Interaction of Cannabis Use and Aging: From Molecule to Mind. J Dual Diagn. marzo de 2020;16(1):140-76.
• Abbott KL, Flannery PC, Gill KS, Boothe DM, Dhanasekaran M, Mani S, et al. Adverse pharmacokinetic interactions between illicit substances and clinical drugs. Drug Metab Rev. febrero de 2020;52(1):44-65.
• Vázquez M, Guevara N, Maldonado C, Guido PC, Schaiquevich P. Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain. Biomed Res Int. 2020;2020:3902740.

2019

• Horvath C, Dalley CB, Grass N, Tola DH. Marijuana Use in the Anesthetized Patient: History, Pharmacology, and Anesthetic Considerations. AANA J. diciembre de 2019;87(6):451-8.
• Freeman AM, Petrilli K, Lees R, Hindocha C, Mokrysz C, Curran HV, et al. How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. Neurosci Biobehav Rev. diciembre de 2019;107:696-712.
• Foster BC, Abramovici H, Harris CS. Cannabis and Cannabinoids: Kinetics and Interactions. Am J Med. noviembre de 2019;132(11):1266-70.
• Echeverria-Villalobos M, Todeschini AB, Stoicea N, Fiorda-Diaz J, Weaver T, Bergese SD. Perioperative care of cannabis users: A comprehensive review of pharmacological and anesthetic considerations. J Clin Anesth. noviembre de 2019;57:41-9.
• Sarzi-Puttini P, Batticciotto A, Atzeni F, Bazzichi L, Di Franco M, Salaffi F, et al. Medical cannabis and cannabinoids in rheumatology: where are we now? Expert Rev Clin Immunol. octubre de 2019;15(10):1019-32.
• Qian Y, Gurley BJ, Markowitz JS. The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications. J Clin Psychopharmacol. octubre de 2019;39(5):462-71.
• Nona CN, Hendershot CS, Le Foll B. Effects of cannabidiol on alcohol-related outcomes: A review of preclinical and human research. Exp Clin Psychopharmacol. agosto de 2019;27(4):359-69.
• White CM. A Review of Human Studies Assessing Cannabidiol’s (CBD) Therapeutic Actions and Potential. J Clin Pharmacol. julio de 2019;59(7):923-34.
• Byars T, Theisen E, Bolton DL. Using Cannabis to Treat Cancer-Related Pain. Semin Oncol Nurs. junio de 2019;35(3):300-9.
• Cogan PS. On healthcare by popular appeal: critical assessment of benefit and risk in cannabidiol based dietary supplements. Expert Rev Clin Pharmacol. junio de 2019;12(6):501-11.
• Cossu AE, Latham LB, Hardacker DM, Jea AH. Pharmacologic chaos: severe hypotension from interactions of anesthetics, marijuana, amphetamines, and paroxetine. J Clin Anesth. 2019;55:17.
• Damkier P, Lassen D, Christensen MMH, Madsen KG, Hellfritzsch M, Pottegård A. Interaction between warfarin and cannabis. Basic Clin Pharmacol Toxicol. enero de 2019;124(1):28-31.
• Delling FN, Vittinghoff E, Dewland TA, Pletcher MJ, Olgin JE, Nah G, et al. Does cannabis legalisation change healthcare utilisation? A population-based study using the healthcare cost and utilisation project in Colorado, USA. BMJ Open. 15 de mayo de 2019;9(5):e027432.
• Khan SP, Pickens TA, Berlau DJ. Perspectives on cannabis as a substitute for opioid analgesics. Pain Manag. 1 de marzo de 2019;9(2):191-203.
• Temple LM, Lampert SL, Ewigman B. Barriers to Achieving Optimal Success with Medical Cannabis: Opportunities for Quality Improvement. J Altern Complement Med. enero de 2019;25(1):5-7.
• Turgeman I, Bar-Sela G. Cannabis for cancer - illusion or the tip of an iceberg: a review of the evidence for the use of Cannabis and synthetic cannabinoids in oncology. Expert Opin Investig Drugs. marzo de 2019;28(3):285-96.
• Twardowski MA, Link MM, Twardowski NM. Effects of Cannabis Use on Sedation Requirements for Endoscopic Procedures. J Am Osteopath Assoc. 15 de abril de 2019.

2018

• Boggs DL, Nguyen JD, Morgenson D, Taffe MA, Ranganathan M. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol. Neuropsychopharmacology. enero de 2018;43(1):142-54 .
• Bouquié R, Deslandes G, Mazaré H, Cogné M, Mahé J, Grégoire M, et al. Cannabis and anticancer drugs: societal usage and expected pharmacological interactions - a review. Fundam Clin Pharmacol. octubre de 2018;32(5):462-84.
• Cannabidiol (Epidiolex) for epilepsy. Med Lett Drugs Ther. 5 de noviembre de 2018;60(1559):182-4.
• Carlini BH, Garrett SB. Drug helplines and adult marijuana users: An assessment in Washington, Colorado, Oregon, and Alaska. Subst Abus. 02 de 2018;39(1):3-5.
• Celius EG, Vila C. The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity. Brain Behav. 2018;8(5):e00962.
• Cooper ZD, Bedi G, Ramesh D, Balter R, Comer SD, Haney M. Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. Neuropsychopharmacology. 2018;43(10):2046-55.
• Cosker E, Schwitzer T, Ramoz N, Ligier F, Lalanne L, Gorwood P, et al. The effect of interactions between genetics and cannabis use on neurocognition. A review. Prog Neuropsychopharmacol Biol Psychiatry. 02 de 2018;82:95-106.
• de Wit H, Sayette M. Considering the context: social factors in responses to drugs in humans. Psychopharmacology (Berl). 2018;235(4):935-45.
• Drugs for chronic insomnia. Med Lett Drugs Ther. 17 de diciembre de 2018;60(1562):201-5.
• Ecker AH, Buckner JD. Cannabis-Related Problems and Social Anxiety: The Mediational Role of Post-Event Processing. Subst Use Misuse. 02 de 2018;53(1):36-41.
• Elvik R. Interpreting interaction effects in estimates of the risk of traffic injury associated with the use of illicit drugs. Accid Anal Prev. abril de 2018;113:224-35.
• Ghovanloo M-R, Shuart NG, Mezeyova J, Dean RA, Ruben PC, Goodchild SJ. Inhibitory effects of cannabidiol on voltage-dependent sodium currents. J Biol Chem. 26 de 2018;293(43):16546-58.
• Hartberg CB, Lange EH, Lagerberg TV, Haukvik UK, Andreassen OA, Melle I, et al. Cortical thickness, cortical surface area and subcortical volumes in schizophrenia and bipolar disorder patients with cannabis use. Eur Neuropsychopharmacol. 2018;28(1):37-47.
• Heidebrecht F, MacLeod MB, Dawkins L. Predictors of heroin abstinence in opiate substitution therapy in heroin-only users and dual users of heroin and crack. Addict Behav. febrero de 2018;77:210-6.
• Hood L. Social Factors and Animal Models of Cannabis Use. Int Rev Neurobiol. 2018;140:171-200.
• Hudson R, Rushlow W, Laviolette SR. Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: implications for neuropsychiatric pathology. Psychopharmacology (Berl). 2018;235(2):447-58.
• Hughes B, Wiessing L, Des Jarlais D, Griffiths P. Could cannabis liberalisation lead to wider changes in drug policies and outcomes? Int J Drug Policy. 2018;51:156-9.
• Ibera C, Shalom B, Saifi F, Shruder J, Davidson E. [EFFECTS OF CANNABIS EXTRACT PREMEDICATION ON ANESTHETIC DEPTH]. Harefuah. marzo de 2018;157(3):162-6.
• Iijima R, Watanabe T, Ishiuchi K, Matsumoto T, Watanabe J, Makino T. Interactions between crude drug extracts used in Japanese traditional Kampo medicines and organic anion-transporting polypeptide 2B1. J Ethnopharmacol. 25 de marzo de 2018;214:153-9.
• Klein A, Potter GR. The three betrayals of the medical cannabis growing activist: From multiple victimhood to reconstruction, redemption and activism. Int J Drug Policy. 2018;53:65-72.
• Kong TY, Kim J-H, Kim DK, Lee HS. Synthetic cannabinoids are substrates and inhibitors of multiple drug-metabolizing enzymes. Arch Pharm Res. julio de 2018;41(7):691-710.
• MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12-9.
• Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV. Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry. 05 de 2018;8(1):181.
• Olfson M, Wall MM, Blanco C. Medical Marijuana and the Opioid Epidemic: Response to Theriault and Schlesinger. Am J Psychiatry. 01 de 2018;175(3):284-5.
• Pellati F, Borgonetti V, Brighenti V, Biagi M, Benvenuti S, Corsi L. Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer. Biomed Res Int. 2018;2018:1691428.
• Porcari GS, Fu C, Doll ED, Carter EG, Carson RP. Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center. Epilepsy Behav. 2018;80:240-6.
• Rong C, Carmona NE, Lee YL, Ragguett R-M, Pan Z, Rosenblat JD, et al. Drug-drug interactions as a result of co-administering Δ9-THC and CBD with other psychotropic agents. Expert Opin Drug Saf. 2018;17(1):51-4.
• Theriault BM, Schlesinger JJ. Potential Impact of Medical Marijuana on Nonmedical Opioid Use. Am J Psychiatry. 01 de 2018;175(3):284.
• Tomko RL, Baker NL, McClure EA, Sonne SC, McRae-Clark AL, Sherman BJ, et al. Incremental validity of estimated cannabis grams as a predictor of problems and cannabinoid biomarkers: Evidence from a clinical trial. Drug Alcohol Depend. 01 de 2018;182:1-7.

2017

• Arellano AL, Papaseit E, Romaguera A, Torrens M, Farré M. Neuropsychiatric and General Interactions of Natural and Synthetic Cannabinoids with Drugs of Abuse and Medicines. CNS Neurol Disord Drug Targets. 2017;16(5):554-66.
• Bagge CL, Borges G. Acute Substance Use as a Warning Sign for Suicide Attempts: A Case-Crossover Examination of the 48 Hours Prior to a Recent Suicide Attempt. J Clin Psychiatry. junio de 2017;78(6):691-6.
• Beaulieu P. Anesthetic implications of recreational drug use. Can J Anaesth. diciembre de 2017;64(12):1236-64.
• Deng L, Ng L, Ozawa T, Stella N. Quantitative Analyses of Synergistic Responses between Cannabidiol and DNA-Damaging Agents on the Proliferation and Viability of Glioblastoma and Neural Progenitor Cells in Culture. J Pharmacol Exp Ther. enero de 2017;360(1):215-24.
• Garin N, Zurita B, Velasco C, Feliu A, Gutierrez M, Masip M, et al. Prevalence and clinical impact of recreational drug consumption in people living with HIV on treatment: a cross-sectional study. BMJ Open. 18 de 2017;7(1):e014105.
• Gaston TE, Friedman D. Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy Behav. 2017;70(Pt B):313-8.
• Hindocha C, Lawn W, Freeman TP, Curran HV. Individual and combined effects of cannabis and tobacco on drug reward processing in non-dependent users. Psychopharmacology (Berl). noviembre de 2017;234(21):3153-63.
• Hodgins S, Klein S. New Clinically Relevant Findings about Violence by People with Schizophrenia. Can J Psychiatry. 2017;62(2):86-93.
• Lake S, Kerr T, Capler R, Shoveller J, Montaner J, Milloy M-J. High-intensity cannabis use and HIV clinical outcomes among HIV-positive people who use illicit drugs in Vancouver, Canada. Int J Drug Policy. 2017;42:63-70 .
• Mahvan TD, Hilaire ML, Mann A, Brown A, Linn B, Gardner T, et al. Marijuana Use in the Elderly: Implications and Considerations. Consult Pharm. 1 de junio de 2017;32(6):341-51.
• Marino S, Idris AI. Emerging therapeutic targets in cancer induced bone disease: A focus on the peripheral type 2 cannabinoid receptor. Pharmacol Res. 2017;119:391-403.
• Martín-Rodríguez MDM, Pulido J, Jiménez-Mejías E, Hoyos J, Lardelli-Claret P, Barrio G. Consistent association between hypnotics/sedatives and non-traffic injuries. Results from a national household survey. Accid Anal Prev. septiembre de 2017;106:379-84.
• Mason BL, Van Enkevort E, Filbey F, Marx CE, Park J, Nakamura A, et al. Neurosteroid Levels in Patients With Bipolar Disorder and a History of Cannabis Use Disorders. J Clin Psychopharmacol. diciembre de 2017;37(6):684-8.
• Miró Ò, Galicia M, Dargan P, Dines AM, Giraudon I, Heyerdahl F, et al. Intoxication by gamma hydroxybutyrate and related analogues: Clinical characteristics and comparison between pure intoxication and that combined with other substances of abuse. Toxicol Lett. 5 de agosto de 2017;277:84-91.
• O’Connell BK, Gloss D, Devinsky O. Cannabinoids in treatment-resistant epilepsy: A review. Epilepsy Behav. 2017;70(Pt B):341-8.
• Rosenberg EC, Patra PH, Whalley BJ. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. Epilepsy Behav. 2017;70(Pt B):319-27.
• Soares VP, Campos AC. Evidences for the Anti-panic Actions of Cannabidiol. Curr Neuropharmacol. 2017;15(2):291-9.
• Tai S, Fantegrossi WE. Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites. Curr Top Behav Neurosci. 2017;32:249-62.
• Thiruchselvam T, Malik S, Le Foll B. A review of positron emission tomography studies exploring the dopaminergic system in substance use with a focus on tobacco as a co-variate. Am J Drug Alcohol Abuse. 2017;43(2):197-214.
• Turgeman I, Bar-Sela G. Cannabis Use in Palliative Oncology: A Review of the Evidence for Popular Indications. Isr Med Assoc J. febrero de 2017;19(2):85-8.
• Volkow ND, Hampson AJ, Baler RD. Don’t Worry, Be Happy: Endocannabinoids and Cannabis at the Intersection of Stress and Reward. Annu Rev Pharmacol Toxicol. 06 de 2017;57:285-308.
• Zaka M, Sehgal SA, Shafique S, Abbasi BH. Comparative in silico analyses of Cannabis sativa, Prunella vulgaris and Withania somnifera compounds elucidating the medicinal properties against rheumatoid arthritis. J Mol Graph Model. 2017;74:296-304.
• Zeremski M, Martinez A. Liver Disease and Fibrosis Assessment in Substance Use-Related Disorders. Clin Pharmacol Drug Dev. marzo de 2017;6(2):164-8.

2016

• Ali A, Carré A, Hassler C, Spilka S, Vanier A, Barry C, et al. Risk factors for substances use and misuse among young people in France: What can we learn from the Substance Use Risk Profile Scale? Drug Alcohol Depend. 1 de junio de 2016;163:84-91.
• Anderson GD, Chan L-N. Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products. Clin Pharmacokinet. 2016;55(11):1353-68.
• Aston ER, Metrik J, Amlung M, Kahler CW, MacKillop J. Interrelationships between marijuana demand and discounting of delayed rewards: Convergence in behavioral economic methods. Drug Alcohol Depend. 1 de diciembre de 2016;169:141-7.
• Bloomfield MAP, Ashok AH, Volkow ND, Howes OD. The effects of Δ9-tetrahydrocannabinol on the dopamine system. Nature. 17 de 2016;539(7629):369-77.
• Bondallaz P, Favrat B, Chtioui H, Fornari E, Maeder P, Giroud C. Cannabis and its effects on driving skills. Forensic Sci Int. noviembre de 2016;268:92-102.
• Cannabis and cannabinoids. Med Lett Drugs Ther. 1 de agosto de 2016;58(1500):97-8.
• Correia RB, Li L, Rocha LM. MONITORING POTENTIAL DRUG INTERACTIONS AND REACTIONS VIA NETWORK ANALYSIS OF INSTAGRAM USER TIMELINES. Pac Symp Biocomput. 2016;21:492-503.
• Darke S, Farrell M. Which medications are suitable for agonist drug maintenance? Addiction. mayo de 2016;111(5):767-74.
• Foster KT, Li N, McClure EA, Sonne SC, Gray KM. Gender Differences in Internalizing Symptoms and Suicide Risk Among Men and Women Seeking Treatment for Cannabis Use Disorder from Late Adolescence to Middle Adulthood. J Subst Abuse Treat. 2016;66:16-22.
• Hartman RL, Brown TL, Milavetz G, Spurgin A, Gorelick DA, Gaffney G, et al. Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships. Drug Test Anal. julio de 2016;8(7):690-701.
• Hua T, Vemuri K, Pu M, Qu L, Han GW, Wu Y, et al. Crystal Structure of the Human Cannabinoid Receptor CB1. Cell. 20 de octubre de 2016;167(3):750-762.e14.
• Jacobus J, Castro N, Squeglia LM, Meloy MJ, Brumback T, Huestis MA, et al. Adolescent cortical thickness pre- and post marijuana and alcohol initiation. Neurotoxicol Teratol. octubre de 2016;57:20-9.
• Lee MR, Weerts EM. Oxytocin for the treatment of drug and alcohol use disorders. Behav Pharmacol. 2016;27(8):640-8.
• Lippiello P, Balestrini S, Leo A, Coppola A, Citraro R, Elia M, et al. From Cannabis to Cannabidiol to Treat Epilepsy, Where Are We? Curr Pharm Des. 2016;22(42):6426-33.
• Notzon DP, Mariani JJ, Pavlicova M, Glass A, Mahony AL, Brooks DJ, et al. Mixed-amphetamine salts increase abstinence from marijuana in patients with co-occurring attention-deficit/hyperactivity disorder and cocaine dependence. Am J Addict. 2016;25(8):666-72.
• Ossato A, Canazza I, Trapella C, Vincenzi F, De Luca MA, Rimondo C, et al. Effect of JWH-250, JWH-073 and their interaction on «tetrad», sensorimotor, neurological and neurochemical responses in mice. Prog Neuropsychopharmacol Biol Psychiatry. 3 de junio de 2016;67:31-50.
• Reece AS, Norman A, Hulse GK. Cannabis exposure as an interactive cardiovascular risk factor and accelerant of organismal ageing: a longitudinal study. BMJ Open. 07 de 2016;6(11):e011891.
• Ross JM, Graziano P, Pacheco-Colón I, Coxe S, Gonzalez R. Decision-Making Does not Moderate the Association between Cannabis Use and Body Mass Index among Adolescent Cannabis Users. J Int Neuropsychol Soc. 2016;22(9):944-9.
• Sherif M, Radhakrishnan R, D’Souza DC, Ranganathan M. Human Laboratory Studies on Cannabinoids and Psychosis. Biol Psychiatry. 1 de abril de 2016;79(7):526-38.
• Volk DW, Lewis DA. The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia. Biol Psychiatry. 1 de abril de 2016;79(7):595-603.

2015

• Abrams DI, Guzman M. Cannabis in cancer care. Clin Pharmacol Ther. junio de 2015;97(6):575-86.
• Carey CE, Agrawal A, Zhang B, Conley ED, Degenhardt L, Heath AC, et al. Monoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: Evidence from an endocannabinoid system-level analysis. J Abnorm Psychol. noviembre de 2015;124(4):860-77.
• Ceccarini J, Kuepper R, Kemels D, van Os J, Henquet C, Van Laere K. [18F]MK-9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users. Addict Biol. marzo de 2015;20(2):357-67.
• Clarke DE, Gonzalez M, Pereira A, Boyce-Gaudreau K, Waldman C, Demczuk L. The impact of knowledge on attitudes of emergency department staff towards patients with substance related presentations: a quantitative systematic review protocol. JBI Database System Rev Implement Rep. octubre de 2015;13(10):133-45.
• Cochran G, Stitzer M, Campbell ANC, Hu M-C, Vandrey R, Nunes EV. Web-based treatment for substance use disorders: differential effects by primary substance. Addict Behav. junio de 2015;45:191-4.
• D’Souza DC, Ranganathan M. Medical Marijuana: Is the Cart Before the Horse? JAMA. 23 de junio de 2015;313(24):2431-2.
• Felton D, Zitomersky N, Manzi S, Lightdale JR. 13-year-old girl with recurrent, episodic, persistent vomiting: out of the pot and into the fire. Pediatrics. abril de 2015;135(4):e1060-1063.
• Filbey FM, McQueeny T, Kadamangudi S, Bice C, Ketcherside A. Combined effects of marijuana and nicotine on memory performance and hippocampal volume. Behav Brain Res. 15 de octubre de 2015;293:46-53.
• Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. agosto de 2015;56(8):1246-51.
• Geresu B. Khat (Catha edulis F.) and cannabinoids: Parallel and contrasting behavioral effects in preclinical and clinical studies. Pharmacol Biochem Behav. noviembre de 2015;138:164-73 .
• Goodman J, Packard MG. The influence of cannabinoids on learning and memory processes of the dorsal striatum. Neurobiol Learn Mem. noviembre de 2015;125:1-14.
• Grant JD, Waldron M, Sartor CE, Scherrer JF, Duncan AE, McCutcheon VV, et al. Parental Separation and Offspring Alcohol Involvement: Findings from Offspring of Alcoholic and Drug Dependent Twin Fathers. Alcohol Clin Exp Res. julio de 2015;39(7):1166-73.
• Hartman RL, Brown TL, Milavetz G, Spurgin A, Gorelick DA, Gaffney G, et al. Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. Clin Chem. junio de 2015;61(6):850-69.
• Hartman RL, Brown TL, Milavetz G, Spurgin A, Pierce RS, Gorelick DA, et al. Cannabis effects on driving lateral control with and without alcohol. Drug Alcohol Depend. 1 de septiembre de 2015;154:25-37.
• Hindocha C, Freeman TP, Schafer G, Gardener C, Das RK, Morgan CJA, et al. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Eur Neuropsychopharmacol. marzo de 2015;25(3):325-34.
• Karoly HC, Bryan AD, Weiland BJ, Mayer A, Dodd A, Feldstein Ewing SW. Does incentive-elicited nucleus accumbens activation differ by substance of abuse? An examination with adolescents. Dev Cogn Neurosci. diciembre de 2015;16:5-15.
• Kollins SH, Schoenfelder EN, English JS, Holdaway A, Van Voorhees E, O’Brien BR, et al. An exploratory study of the combined effects of orally administered methylphenidate and delta-9-tetrahydrocannabinol (THC) on cardiovascular function, subjective effects, and performance in healthy adults. J Subst Abuse Treat. enero de 2015;48(1):96-103.
• Lamy S, Laqueille X, Thibaut F. [Consequences of tobacco, cocaine and cannabis consumption during pregnancy on the pregnancy itself, on the newborn and on child development: A review]. Encephale. junio de 2015;41 Suppl 1:S13-20.
• Le Roux G, Bruneau C, Lelièvre B, Bretaudeau Deguigne M, Turcant A, Harry P, et al. Recreational phenethylamine poisonings reported to a French poison control center. Drug Alcohol Depend. 1 de septiembre de 2015;154:46-53.
• Lee TT-Y, Gorzalka BB. Evidence for a Role of Adolescent Endocannabinoid Signaling in Regulating HPA Axis Stress Responsivity and Emotional Behavior Development. Int Rev Neurobiol. 2015;125:49-84.
• McRae-Clark AL, Baker NL, Gray KM, Killeen TK, Wagner AM, Brady KT, et al. Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial. Drug Alcohol Depend. 1 de noviembre de 2015;156:29-37.
• Metz TD, Stickrath EH. Marijuana use in pregnancy and lactation: a review of the evidence. Am J Obstet Gynecol. diciembre de 2015;213(6):761-78.
• Miovský M, Voňková H, Gabrhelík R, Šťastná L. Universality properties of school-based preventive intervention targeted at cannabis use. Prev Sci. febrero de 2015;16(2):189-99.
• Moeller SJ, Beebe-Wang N, Schneider KE, Konova AB, Parvaz MA, Alia-Klein N, et al. Effects of an opioid (proenkephalin) polymorphism on neural response to errors in health and cocaine use disorder. Behav Brain Res. 15 de octubre de 2015;293:18-26.
• Newville H, Berg KM, Gonzalez JS. The interaction of active substance use, depression, and antiretroviral adherence in methadone maintenance. Int J Behav Med. abril de 2015;22(2):214-22.
• Nielsen MKK, Johansen SS, Linnet K. Evaluation of poly-drug use in methadone-related fatalities using segmental hair analysis. Forensic Sci Int. marzo de 2015;248:134-9 .
• Peeters SCT, van Bronswijk S, van de Ven V, Gronenschild EHBM, Goebel R, van Os J, et al. Cognitive correlates of frontoparietal network connectivity «at rest» in individuals with differential risk for psychotic disorder. Eur Neuropsychopharmacol. noviembre de 2015;25(11):1922-32.
• Peeters SCT, van de Ven V, Gronenschild EHBM, Patel AX, Habets P, Goebel R, et al. Default mode network connectivity as a function of familial and environmental risk for psychotic disorder. PLoS ONE. 2015;10(3):e0120030.
• Price JS, McQueeny T, Shollenbarger S, Browning EL, Wieser J, Lisdahl KM. Effects of marijuana use on prefrontal and parietal volumes and cognition in emerging adults. Psychopharmacology (Berl). agosto de 2015;232(16):2939-50.
• Schneider R, Ottoni GL, de Carvalho HW, Elisabetsky E, Lara DR. Temperament and character traits associated with the use of alcohol, cannabis, cocaine, benzodiazepines, and hallucinogens: evidence from a large Brazilian web survey. Braz J Psychiatry. marzo de 2015;37(1):31-9.
• Schuster RM, Crane NA, Mermelstein R, Gonzalez R. Tobacco may mask poorer episodic memory among young adult cannabis users. Neuropsychology. septiembre de 2015;29(5):759-66.
• Subbaraman MS, Kerr WC. Simultaneous versus concurrent use of alcohol and cannabis in the National Alcohol Survey. Alcohol Clin Exp Res. mayo de 2015;39(5):872-9.
• Thorpy MJ, Dauvilliers Y. Clinical and practical considerations in the pharmacologic management of narcolepsy. Sleep Med. enero de 2015;16(1):9-18.
• Tormey WP. Newspaper reports from the Coroners Court in Ireland are used to reveal the potential complexity and need for reform in forensic toxicology and medicine services. J Forensic Leg Med. mayo de 2015;32:47-52.
• Wøien V-A, Horwitz H, Høgberg LCG, Askaa B, Jürgens G. [Cannabis--abuse and consequences]. Ugeskr Laeg. 2 de febrero de 2015;177(6).

2014

• Cilio MR, Thiele EA, Devinsky O. The case for assessing cannabidiol in epilepsy. Epilepsia. junio de 2014;55(6):787-90.
• Davis GP, Surratt HL, Levin FR, Blanco C. Antiretroviral medication: an emerging category of prescription drug misuse. Am J Addict. diciembre de 2014;23(6):519-25.
• Delta-9-tetrahydrocannabinol + cannabidiol. A reasonable option for some patients with multiple sclerosis. Prescrire Int. junio de 2014;23(150):145-8.
• Lile JA, Kelly TH, Hays LR. Separate and combined effects of the GABAA positive allosteric modulator diazepam and Δ9-THC in humans discriminating Δ9-THC. Drug Alcohol Depend. 1 de octubre de 2014;143:141-8.
• O’Tuathaigh CMP, Gantois I, Waddington JL. Genetic dissection of the psychotomimetic effects of cannabinoid exposure. Prog Neuropsychopharmacol Biol Psychiatry. 3 de julio de 2014;52:33-40.
• Richardson P. The Case of the cannabis conundrum. ONS Connect. diciembre de 2014;29(4):11.